Arrowhead Pharmaceuticals Inc财报电话会议总结 (Q2/2025) 2025财年第二季度每股收益达2.75美元，远超预期的-0.45美元；营收飙升至5.427亿美元，超过1.279亿美元的预期 净利润达3.704亿美元，主要得益于与Sarepta的授权协议；盘后交易中股价上涨8.95% 现金和投资达11亿美元；6.09倍的流动比率显示出强劲的短期流动 ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Tigress Arrowhead (T-84), one of Ranthambore's most celebrated big cats, passed away at the age of 14, forest officials confirmed in an Instagram post on Thursday. Her death came just hours after ...

Jaipur: Arrowhead (T-84), a tigress in Ranthambore, died of a bone tumour on Thursday, the same day her daughter Kankati (T-2507), who killed a 7-year-old in April, was relocated to Mukundra Hills ...

Analyst Price Forecast Suggests 354.63% Upside As of June 2, 2025, the average one-year price target for Sarepta Therapeutics is $95.20/share. The forecasts range from a low of $40.40 to a high of ...

The Arrowhead partnership has the potential to address previous concerns about Sarepta’s long-term growth prospects and pipeline sustainability. By leveraging this collaboration, Sarepta may be able ...

The price for the Sarepta Therapeutics stock decreased slightly today. Compared to yesterday there is a change of -€0.025 (-0.130%). Currently there is a rather positive sentiment for Sarepta ...

Sarepta's consensus price target among the 25 MarketBeat-tracked analysts is around $70, implying a potential upside of more than 230%. This huge divergence likely reflects the fact that Sarepta ...

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law Leading securities law ...

Sarepta shares dropped 27% after the first death in March. BMO lowered its price target to $70, warning of risks to 2025 revenue guidance and potential regulatory action affecting non-ambulatory ...